Beyond amyloid and tau, I would say the most exciting shift is towards a mechanism-based precision therapy approach that targets the underlying biology and pathobiology of the disease. And we’re really starting to see emerging therapeutic strategies are really gaining momentum, and these are targeting novel mechanisms consistent with the biology of aging, such as inflammation, autophagy, and metabolic dysfunction...
Beyond amyloid and tau, I would say the most exciting shift is towards a mechanism-based precision therapy approach that targets the underlying biology and pathobiology of the disease. And we’re really starting to see emerging therapeutic strategies are really gaining momentum, and these are targeting novel mechanisms consistent with the biology of aging, such as inflammation, autophagy, and metabolic dysfunction. And based on this, what’s become clear is that Alzheimer’s is not a single-target disease, and the future really lies in precision combination therapies that are targeted and tailored to each person. And these will be guided by biomarkers and diagnostics that are really coming to the fore. So some of the portfolio companies that I’m really excited about include Coya, which is testing a novel combination therapy, and this targets neuroinflammation, one of the mechanisms that I mentioned. And this allows the drug combination to be able to target abnormal immune function that treats frontotemporal degeneration. Another example is Modulo Bio, and they’re taking a different approach to looking at neuroinflammation. So they’re working on reprogramming microglia, which are the resident immune cells in the brain. And they’re reprogramming these microglia into a neuroprotective state to treat FTD as well as the other neurodegenerative disease, ALS. A third company that I’m particularly excited about is Therini. And they’re developing a drug to target inflammatory fibrin. So this therapy selectively prevents microglia and macrophages, another immune cell, so that this will allow a reduction in inflammation, but will not affect the coagulation that normally occurs with fibrin. From a biomarker and diagnostics perspective, I’m really excited about our investment in Alamar, which is developing a diagnostic platform for a new generation of blood-based diagnostics. And this will be applicable for Alzheimer’s disease as well as other related neurodegenerative diseases. You may have also heard the very exciting news that we now have two FDA-approved blood tests for Alzheimer’s disease, and one of these was funded through ADDF, FujiRebio. So that is very exciting for both patients as well as for the development of novel therapeutics. And then finally, C2N’s PrecivityAD test was the first to market. And again, ADDF helped provide that seed funding.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
